Sort
82,697 grants matching “vaccine development”
Administrative Core - Galveston National Laboratory BSL4 Operations
$1,020,663James W. Leduc · University Of Texas Med Br Galveston · UC7 · FY2020 · AI
PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREV
$1,020,618David McCormick · Iit Research Institute · N01 · FY2024 · CA
Medical Scientist Training Program
$1,020,603Terence S. Dermody · Vanderbilt University · T32 · FY2013 · GM
Tuberculosis Research Unit
$1,020,532W. Henry Boom · Case Western Reserve University · N01 · FY2011 · AI
Project 1: Immunological imprinting and immune correlates of antibody and B cell responses in natural dengue virus infections
$1,020,372Eva Harris · University Of California Berkeley · P01 · FY2025 · AI
Project 2 - Novel Therapeutics for Emerging Alphavirus
$1,020,148Daniel N Streblow · University Of Alabama At Birmingham · U19 · FY2020 · AI
Modeling Inflammation in HIV Transmission
$1,019,992Christopher Miller · University Of California At Davis · R01 · FY2016 · AI
Project 2 - Novel Therapeutics for Emerging Alphavirus
$1,019,887Daniel N Streblow · University Of Alabama At Birmingham · U19 · FY2021 · AI
Bytes to Bedside: Collaborative Development for Translational Clinical Decision Support
$1,019,879Eric Steven Kirkendall · Wake Forest University Health Sciences · UG3 · FY2024 · TR
Structural Biology of Influenza Epitopes
$1,019,860Audray Harris · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Center of Excellence for High Throughput Proteogenomic Characterization
$1,019,814Steven A. Carr · Broad Institute, Inc. · U24 · FY2024 · CA
Preclinical development of a biological antiviral for universal influenza treatment and prophylaxis using a novel nucleic acid delivery platform
$1,019,722Lyndsey Linke · Sivec Biotechnologies, Llc · R44 · FY2021 · AI
Vaccines Designed From Analysis of Recent HIV Infections
$1,019,667Vaxgen, Inc. · R44 · FY2003 · AI
Novel Adjuvants/Delivery Systems for Biodefense Vaccines
$1,019,625Novartis Vaccines And Diagnostics, Inc. · U01 · FY2003 · AI
A multi-tiered approach to develop validated assays to predict efficacy of a tetravalent live attenuated Dengue Virus vaccine in Phase II and Phase III clinical trials
$1,019,293Rafick-Pierre Sekaly · Case Western Reserve University · R01 · FY2017 · AI
The impact of antiretroviral therapy on fetal immune system development in SIV-exposed rhesus macaques
$1,019,108Oleg Varlamov · Oregon Health & Science University · R01 · FY2025 · HD
IND-enabling development for IN-002, an inhaled muco-trapping mAb against respiratory syncytial virus
$1,018,961Jeff T Hutchins · Inhalon Biopharma, Inc. · R44 · FY2023 · AI
UCSF HIV Clinical Trials Unit
$1,018,836Diane V Havlir · University Of California, San Francisco · U01 · FY2009 · AI
Human Papillomavirus and Polyomavirus Associated Malignancies.
$1,018,780Denise A. Galloway · Fred Hutchinson Cancer Center · R35 · FY2022 · CA
Salmonella Group C as part of a multivalent Salmonella vaccine
$1,018,638Sharon Mei Tennant · University Of Maryland Baltimore · U19 · FY2017 · AI
National Resource for Automated Molecular Microscopy
$1,018,585Bridget Olivia Carragher · Scripps Research Institute, The · P41 · FY2014 · GM
VANDERBILT ADULT AIDS CLINICAL TRIALS UNIT
$1,018,550Vanderbilt University · U01 · FY2000 · AI
Improved Treatment of Colorectal Cancer with CF10
$1,018,545William H Gmeiner · Deep Creek Pharma, Llc · R42 · FY2024 · CA
Pathogenesis of Tick-Borne Flavivirus Infections
$1,018,434Marshall Bloom · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
Qualification of Assays to Measure Human T-cell Responses Against Mycobacterial Lipid Antigens
$1,018,336Chetan Seshadri · University Of Washington · R01 · FY2016 · AI